Immix Biopharma – executive interview

Published on 20 September 2022

Immix Biopharma is developing a new class of tissue-specific therapeutics (TSTx) targeting oncology and immune-dysregulated disease. In Q422, the company’s lead clinical asset, IMX-110, is expected to begin a Phase IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumours in combination with the ICI tislelizumab. The company also has a preclinical pipeline based on the TSTx technology. In this video, Immix Biopharma’s CEO, Dr Ilya Rachman, provides an overview of the company’s strategy and approach.

Share this with friends and colleagues